File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s13238-020-00804-9
- Scopus: eid_2-s2.0-85096930316
- PMID: 33252713
- WOS: WOS:000594790200001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Targeting the alternative bile acid synthetic pathway for metabolic diseases
Title | Targeting the alternative bile acid synthetic pathway for metabolic diseases |
---|---|
Authors | |
Keywords | alternative pathway bile acids gut microbiota metabolic diseases |
Issue Date | 2021 |
Citation | Protein and Cell, 2021, v. 12, n. 5, p. 411-425 How to Cite? |
Abstract | The gut microbiota is profoundly involved in glucose and lipid metabolism, in part by regulating bile acid (BA) metabolism and affecting multiple BA-receptor signaling pathways. BAs are synthesized in the liver by multi-step reactions catalyzed via two distinct routes, the classical pathway (producing the 12α-hydroxylated primary BA, cholic acid), and the alternative pathway (producing the non-12α-hydroxylated primary BA, chenodeoxycholic acid). BA synthesis and excretion is a major pathway of cholesterol and lipid catabolism, and thus, is implicated in a variety of metabolic diseases including obesity, insulin resistance, and nonalcoholic fatty liver disease. Additionally, both oxysterols and BAs function as signaling molecules that activate multiple nuclear and membrane receptor-mediated signaling pathways in various tissues, regulating glucose, lipid homeostasis, inflammation, and energy expenditure. Modulating BA synthesis and composition to regulate BA signaling is an interesting and novel direction for developing therapies for metabolic disease. In this review, we summarize the most recent findings on the role of BA synthetic pathways, with a focus on the role of the alternative pathway, which has been under-investigated, in treating hyperglycemia and fatty liver disease. We also discuss future perspectives to develop promising pharmacological strategies targeting the alternative BA synthetic pathway for the treatment of metabolic diseases. |
Persistent Identifier | http://hdl.handle.net/10722/342250 |
ISSN | 2023 Impact Factor: 13.6 2023 SCImago Journal Rankings: 4.412 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jia, Wei | - |
dc.contributor.author | Wei, Meilin | - |
dc.contributor.author | Rajani, Cynthia | - |
dc.contributor.author | Zheng, Xiaojiao | - |
dc.date.accessioned | 2024-04-17T07:02:26Z | - |
dc.date.available | 2024-04-17T07:02:26Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Protein and Cell, 2021, v. 12, n. 5, p. 411-425 | - |
dc.identifier.issn | 1674-800X | - |
dc.identifier.uri | http://hdl.handle.net/10722/342250 | - |
dc.description.abstract | The gut microbiota is profoundly involved in glucose and lipid metabolism, in part by regulating bile acid (BA) metabolism and affecting multiple BA-receptor signaling pathways. BAs are synthesized in the liver by multi-step reactions catalyzed via two distinct routes, the classical pathway (producing the 12α-hydroxylated primary BA, cholic acid), and the alternative pathway (producing the non-12α-hydroxylated primary BA, chenodeoxycholic acid). BA synthesis and excretion is a major pathway of cholesterol and lipid catabolism, and thus, is implicated in a variety of metabolic diseases including obesity, insulin resistance, and nonalcoholic fatty liver disease. Additionally, both oxysterols and BAs function as signaling molecules that activate multiple nuclear and membrane receptor-mediated signaling pathways in various tissues, regulating glucose, lipid homeostasis, inflammation, and energy expenditure. Modulating BA synthesis and composition to regulate BA signaling is an interesting and novel direction for developing therapies for metabolic disease. In this review, we summarize the most recent findings on the role of BA synthetic pathways, with a focus on the role of the alternative pathway, which has been under-investigated, in treating hyperglycemia and fatty liver disease. We also discuss future perspectives to develop promising pharmacological strategies targeting the alternative BA synthetic pathway for the treatment of metabolic diseases. | - |
dc.language | eng | - |
dc.relation.ispartof | Protein and Cell | - |
dc.subject | alternative pathway | - |
dc.subject | bile acids | - |
dc.subject | gut microbiota | - |
dc.subject | metabolic diseases | - |
dc.title | Targeting the alternative bile acid synthetic pathway for metabolic diseases | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1007/s13238-020-00804-9 | - |
dc.identifier.pmid | 33252713 | - |
dc.identifier.scopus | eid_2-s2.0-85096930316 | - |
dc.identifier.volume | 12 | - |
dc.identifier.issue | 5 | - |
dc.identifier.spage | 411 | - |
dc.identifier.epage | 425 | - |
dc.identifier.eissn | 1674-8018 | - |
dc.identifier.isi | WOS:000594790200001 | - |